Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Company announces acceptance of DURIN IND application and clinical protocol
January 20th, 2005
DURECT Corp. (DRRX), an emerging specialty-pharmaceutical systems company, and Voyager Pharmaceutical Corp., a privately held specialty-pharmaceutical company focused on diseases of aging, announced the acceptance of the investigational new drug application (IND) and clinical protocol by the FDA (U.S. Food and Drug Administration) for a DURIN-based leuprolide acetate treatment of Alzheimer disease under development. This trial will consist of a pharmacokinetic study in normal, healthy volunteers. The objectives of the clinical study are to determine the safety and tolerability of the DURIN leuprolide implant, as well as evaluate the pharmacokinetic profile of the...
Source: Women's Health Weekly (2005-01-20)
|
